Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 17/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | C1R | P00736 | 1/20 | 0.55 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29405904 | 0.81 | ELANE (0.81) | ELANEMEN1KMT2AC1RPDE10A | |
| SCHEMBL692733 | 0.81 | ELANE (0.81) | ELANEMEN1KMT2AC1RPDE10A | |
| SCHEMBL6136297 | 0.81 | ELANE (0.83) | ELANEMEN1KMT2AC1RPDE10A | |
| SCHEMBL10550516 | 0.78 | ELANE (1.00) | ELANEMEN1KMT2AC1R | |
| SCHEMBL29444886 | 0.78 | ELANE (0.76) | ELANEMEN1KMT2AC1RPDE10A | |
| SCHEMBL2812822 | 0.78 | ELANE (0.76) | ELANEMEN1KMT2AC1R | |
| SCHEMBL4408698 | 0.78 | ELANE (0.70) | ELANEMEN1KMT2AC1RPDE10A | |
| Benzene SCHEMBL6030702 | 0.78 | MAPT (0.61) | MEN1KMT2A | |
| SCHEMBL692829 | 0.78 | ELANE (0.76) | ELANEMEN1KMT2AC1RPDE10A | |
| SCHEMBL9268046 | 0.77 | ELANE (0.67) | ELANEMEN1KMT2AC1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-3989698-A | ACYLATION, TERTIARY AMINE CATALYST, ISATOIC ANHYDRIDE | THE SHERWIN-WILLIAMS COMPANY (US) | 1976-11-02 | — | — | US | claimed |
| US-20130209515-A1 | ANTI-INFECTIVE AND IMMUNOMODULATORY COMPOUNDS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2013-08-15 | — | — | US | disclosed |
| US-20090215819-A1 | ANTI-INFECTIVE AND IMMUNOMODULATORY COMPOUNDS | NIH - DEITR | 2009-08-27 | — | — | US | disclosed |
| WO-2006130832-A2 | ANTI-INFECTIVE AND IMMUNOMODULATORY COMPOUNDS | THE GENERAL HOSPITAL CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| US-20050032795-A1 | 2-Amino-benzoxazinones for the treatment of herpes simplex virus | G.D. SEARLE & CO. (US) | 2005-02-10 | — | — | US | disclosed |
| US-20050032793-A1 | 2-amino-benzoxazinones for the treatment of viral infections | G.D. SEARLE & CO. (US) | 2005-02-10 | — | — | US | disclosed |
| US-6806269-B1 | EFFECTIVE AT LOWER CONCENTRATIONS; SUCH AS 6-(((1,1-DIMETHYL-ETHOXY)CARBONYL)AMINO)-5-METHYL-2-(METHYL(PHENYLMETHYL) -AMINO)-4H-3,1-BENZOXAZIN-4-ONE | G. D. SEARLE & COP | 2004-10-19 | — | — | US | disclosed |
| EP-1122245-B1 | 2-Amino-benzoxazinones for the treatment of viral infections | SEARLE & CO (US) | 2004-07-07 | — | — | EP | disclosed |
| US-20040116420-A1 | Remedial agent for viral infectious disease | ASAHI KASEI PHARMA CORPORATION (JP) | 2004-06-17 | — | — | US | disclosed |
| EP-1403269-A1 | REMEDIAL AGENT FOR VIRAL INFECTIOUS DISEASE | Asahi Kasei Pharma Corporation (JP) | 2004-03-31 | — | — | EP | disclosed |
| EP-0317645-B1 | 4H-3,1-BENZOXAZIN-4-ONE COMPOUNDS AND SERINE PROTEASE-INHIBITING MEDICINAL COMPOSITION CONTAINING SAME | TEIJIN LIMITED (JP) | 1993-09-15 | — | — | EP | disclosed |
| EP-0466944-A1 | 4H-3,1-BENZOXAZIN-4-ONE COMPOUND AND ELASTASE INHIBITOR COMPOSITION CONTAINING THE SAME | TEIJIN LIMITED (JP) | 1992-01-22 | — | — | EP | disclosed |
| US-4980287-A | ANTIINFLAMMATORY AGENTS; INHIBITOR OF DEGENERATION AND DESTRUCTION OF TISSUES | TEIJIN LIMITED (JP) | 1990-12-25 | — | — | US | disclosed |
| EP-0147211-B1 | 4H-3,1-BENZOXAZIN-4-ONES AND RELATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESSES FOR THEIR PREPARATION | SYNTEX (U.S.A.) INC. (US) | 1990-09-12 | — | — | EP | disclosed |
| EP-0317645-A1 | 4H-3,1-BENZOXAZIN-4-ONE COMPOUNDS AND SERINE PROTEASE-INHIBITING MEDICINAL COMPOSITION CONTAINING SAME | TEIJIN LIMITED (JP) | 1989-05-31 | — | — | EP | disclosed |
| US-4745116-A | INHIBITORS OF SERINE PROTEASE | SYNTEX (U.S.A.) INC. (US) | 1988-05-17 | — | — | US | disclosed |
| US-4665070-A | SERINE PROTEINASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1987-05-12 | — | — | US | disclosed |
| US-4657893-A | ANTIINFLAMMATORY AGENTS | SYNTEX (U.S.A.) INC. (US) | 1987-04-14 | — | — | US | disclosed |
| EP-0206323-A1 | 2-Oxy-4H-3,1-benzoxazin-4-one derivatives and related compounds | SYNTEX (U.S.A.) INC. (US) | 1986-12-30 | — | — | EP | disclosed |
| EP-0147211-A2 | 4H-3,1-benzoxazin-4-ones and related compounds, pharmaceutical compositions containing them, and processes for their preparation | SYNTEX (U.S.A.) INC. (US) | 1985-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032793-A1 | 2-amino-benzoxazinones for the treatment of viral infections | IFNAR1, IL4I1, ACE2 | ELANE 1199/4885MEN1 4124/4885KMT2A 1859/4885 |
| US-20130209515-A1 | ANTI-INFECTIVE AND IMMUNOMODULATORY COMPOUNDS | IRF3, MAVS, MIF | ELANE 139/4885MEN1 3367/4885KMT2A 4452/4885 |
| US-20090215819-A1 | ANTI-INFECTIVE AND IMMUNOMODULATORY COMPOUNDS | IRF3, MAVS, MIF | ELANE 139/4885MEN1 3367/4885KMT2A 4452/4885 |
| US-20050032795-A1 | 2-Amino-benzoxazinones for the treatment of herpes simplex virus | GABBR1, GABBR2, EBNA1BP2 | ELANE 1052/4885MEN1 4479/4885KMT2A 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.